文献速递心律失常血脂与心血管预防

永久性颈动脉滤器预防房颤患者卒中的CAPTURE试验

Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial.
PubMed 文献 · J Am Coll Cardiol · 2019-05-11

CAPTURE是一项多中心、非随机、首次人体试验,评估双侧颈总动脉永久性线圈滤器(捕获>1.4 mm栓子)用于不适合口服抗凝药的房颤患者卒中预防的可行性与安全性。25例患者(CHA2DS2-VASc 4.4±1.0)中手术成功92%,无器械/操作相关主要不良事件,6个月随访中4例发现无症状血栓且均经皮下肝素溶解。结论认为该技术可行且安全。

要点

  • 双侧颈总动脉永久滤器置入技术成功率高(92%),无器械/操作相关主要不良事件。
  • 术后6个月随访发现4例无症状血栓,均经皮下肝素溶解。
  • 研究为首次人体非随机试验,样本量小,需进一步验证。

核心结论

  • 永久性颈动脉滤器置入用于房颤患者卒中预防在技术上可行且安全。

研究设计与样本

  • 多中心、非随机、首次人体临床试验(CAPTURE),在3个中心纳入25例房颤患者。
  • 入选标准包括CHA2DS2-VASc≥2、不适合口服抗凝药、颈总动脉尺寸4.8-9.8 mm、无颈动脉狭窄>30%。

主要发现

  • 手术成功率为92%(23/25例),1例单侧置入。
  • 无器械/操作相关主要不良事件;穿刺部位轻微血肿/水肿发生5/25例(20%)。
  • 平均随访6个月,4例患者检测到无症状血栓(1例双侧,4例单侧), adjudicated为捕获(n=3)、未分类(n=2)或原位(n=0),均经皮下肝素溶解。
  • 1例患者发生2次与器械/操作无关的轻微卒中。

关键数值与推荐

  • 滤器设计用于捕获直径>1.4 mm的栓子。
  • 患者术后接受阿司匹林/氯吡格雷3个月,之后长期阿司匹林。
  • 主要终点为手术成功(双侧滤器正确位置)和30天主要不良事件(死亡、卒中、大出血、滤器移位、颈总动脉血栓或狭窄)。

临床怎么用

  • 对于不适合口服抗凝药的房颤高卒中风险患者,永久性颈动脉滤器可能成为一种替代卒中预防策略。
  • 术后需抗血小板治疗并定期颈动脉超声随访以监测血栓和狭窄。

局限性

  • 非随机、首次人体试验,样本量小(25例),随访时间短(平均6个月)。
  • 未设对照组,无法评估相对疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with high stroke risk and atrial fibrillation who are unsuitable to oral anticoagulants (OACs) require other stroke prevention strategies. A novel permanent coil filter directly placed into both common carotid arteries (CCAs) was designed to capture emboli >1.4 mm in diameter. OBJECTIVES: The multicenter, nonrandomized, first-in-human clinical CAPTURE (Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients) trial sought to determine the feasibility and safety of bilateral CCA filter placement. METHODS: Eligible patients had atrial fibrillation, CHA2DS2-VASc (Congestive heart failure, Hypertension, Age 75 years, Diabetes, Stroke/transient ischemic attack, Vascular disease, Age 65 to 74 years, Sex category) ≥2, OAC unsuitability, CCA size 4.8 to 9.8 mm, and no carotid stenosis >30%. Under ultrasound guidance, after direct transcutaneous carotid puncture with a 24-gauge needle, a motorized unit expels the filter to unfurl in the artery. Patients received aspirin/clopidogrel for 3 months, and aspirin thereafter. Primary endpoints were: 1) procedural success-bilateral, properly positioned CCA filters; and 2) 30-day incidence of major adverse events-death, stroke, major bleeding, filter migration, CCA thrombus, or stenosis. Carotid ultrasounds were conducted post-procedure, pre-discharge, at 1 week, and at 1, 3, 6, and 12 months. RESULTS: At 3 centers, 25 patients were enrolled: age 71 ± 9 years, CHA2DS2-VASc = 4.4 ± 1.0, prior embolism in 48%. Procedure success was 92% (23 of 25 patients); 1 patient had unilateral deployment. There were no device/procedure-related major adverse events; minor puncture site hematomas/edema occurred in 5 of 25 (20%). After 6-month mean follow-up, asymptomatic thrombi were detected in 4 patients (1 bilateral, 4 unilateral), adjudicated as captured (n = 3), unclassified (n = 2), or in situ (n = 0). In all patients, the thrombi dissolved with subcutaneous heparin. In 1 patient, 2 device/procedure-unrelated minor strokes occurred. CONCLUSIONS: Permanent carotid filter placement for stroke prophylaxis is technically feasible and safe. (Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients [CAPTURE]; NCT03571789).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reddy VY, Neuzil P, de Potter T, et al. Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial. J Am Coll Cardiol. 2019. PMID: 31085320. doi:10.1016/j.jacc.2019.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。